CMChristopher D. Miller

Christopher D. Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher D. Miller has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Ben W. Lomaestro

    Department of Pharmacy, Albany Medical Center Hospital

    1 shared publication
  • David S. Perlin

    Albany, New York; and Public Research Institute, Newark, New Jersey

    1 shared publication
  • John J. Faragon

    Division of HIV Medicine, Albany Medical College, Albany, New York

    1 shared publication
  • Ramy El‐Kholi

    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York

    1 shared publication
  • Steven Park

    Albany, New York; and Public Research Institute, Newark, New Jersey

    1 shared publication
  • Thomas P. Lodise

    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York

    1 shared publication

Latest Publications

  • Prevalence and Risk Factors for Clinically Significant Drug Interactions with Antiretroviral Therapy

    by Christopher D. Miller, Ramy El‐Kholi, John J. Faragon, Thomas P. Lodise

    Study Objectives. To identify the prevalence and types of clinically significant drug interactions (CSDIs) in the drug regimens of patients with human immunodeficiency virus (HIV) infection who were receiving antiretroviral therapy and to explore risk factors for these CSDIs.Design. Retrospective medical record review.Setting. Academic HIV specialty clinic.Patients. One hundred fifty‐three randomly selected patients with HIV infection who were receiving antiretroviral therapy from May 1‐September 30, 2006.Measurements and Main Results. Data were collected on patient demographics, date of HIV diagnosis, most recent viral load and CD4+ count, Centers for Disease Control and Prevention HIV classification, and comorbid conditions. Patients' drug regimens were analyzed for total and clinically significant antiretroviral drug interactions using three resources. Logistic regression and classification and regression tree analysis were used to identify independent CSDI predictors. Clinically significant drug interactions were defined as drug interactions that required a dosage adjustment or consisted of a drug combination that is contraindicated due to its high potential for clinical adverse effects. Of the 153 patients, at least one CSDI was found in 41.2% of their regimens: 34.6% with at least one drug interaction that required a dosage adjustment, 2.0% with at least one contraindicated drug combination, and 4.6% with at least one of each of these CSDIs. In the logistic regression model, risk factors independently associated with CSDIs were age older than 42 years (odds ratio [OR] 2.9, 95% CI 1.2–7.1), more than three comorbid conditions (OR 3.0, 95% CI 1.4–6.6), treatment with more than three antiretroviral agents (OR 2.4, 95% CI 1.0–5.8), and treatment with a protease inhibitor (OR 11.5, 95% CI 4.2–31.2). When directly compared, CSDIs were more prevalent among protease inhibitor–based than nonnucleoside reverse transcriptase inhibitor–based regimens (pConclusion. Clinically significant drug interactions are highly prevalent among HIV‐infected patients receiving antiretroviral therapy. Knowledge of the risk factors for CSDIs may help clinicians recognize and manage CSDIs.


  • Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin

    by Christopher D. Miller, Ben W. Lomaestro, Steven Park, David S. Perlin

    Candida esophagitis, a defining illness of acquired immunodeficiency syndrome (AIDS), requires systemic antifungal therapy. Candida albicans can become resistant to commonly administered azole antifungal agents. An attractive alternative is caspofungin, an echinocandin antifungal that has generally displayed predictable activity against C. albicans. We report the case of a 29‐year‐old woman with AIDS who developed recurrent esophagitis caused by a strain of C. albicans that showed reduced susceptibility to caspofungin (elevated minimum inhibitory concentration of 8 mg/L). Analysis of the strain revealed that it contained a serine‐to‐proline substitution at position 645 in the FKS1 gene. Clinicians who prescribe caspofungin to treat esophagitis caused by C. albicans should recognize the potential risk, albeit slight, for acquired resistance to caspofungin and possibly other echinocandin antifungal agents in the face of persistent disease. In patients who are refractory or unresponsive to caspofungin therapy, susceptibility testing and/or alternative therapy should be considered.